Latest Period
Q2 2026
Security Snapshot
Quince Therapeutics, Inc. - Common Stock, par value $0.001 per share (QNCX) Institutional Ownership
CUSIP: 22053A305
13F Institutional Holders and Ownership History for Q2 2026
Institutions Reporting
25
Shares (Excl. Options)
260,094
Price
$18.19
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Symbol
- QNCX on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 260,094
- Total 13F value
- $4,742,596
- Portfolio coverage rank
- 0%
- Share change
- +260,094
- Value change
- +$4,742,596
- Number of holders
- 25
- Shares outstanding
- 1,019,878
- SEC-reported price per share
- $23.03
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- QNCX - Quince Therapeutics, Inc. - Common Stock, par value $0.001 per share is tracked under CUSIP 22053A305.
- 25 institutions reported positions in Q2 2026.
- 4 significant owners is listed from Schedule 13D/13G reporting.
Change
- Latest quarter on this page is Q2 2026.
- Additional quarter-over-quarter change detail appears as history expands.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 25 institutions filings for Q2 2026.
Security key
22053A305
Latest holder period
Q2 2026
13F holders
25
13D/G owners
4
CIK / CUSIP context first
Open Q2 2026 holders
QNCX full holder history
Quince Therapeutics, Inc. SEC filings
Quince Therapeutics, Inc. company facts
Quince Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 22053A305:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
4
Security
QNCX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Cormorant Asset Management, LP | 10% | $1,863,500 | 108,029 | Cormorant Asset Management, LP | 30 Jun 2026 | |||
| BALYASNY ASSET MANAGEMENT L.P. | 10% | $1,685,308 | 97,699 | BALYASNY ASSET MANAGEMENT L.P. | 30 Jun 2026 | |||
| Ikarian Capital, LLC | 9% | $1,583,360 | 91,789 | Ikarian Capital, LLC | 30 Jun 2026 | |||
| Squadron Capital Management LLC | 5.6% | $951,734 | 55,173 | Squadron Master Fund LP | 28 Jul 2026 |
As of 30 Jun 2026, 25 institutional investors reported holding 260,094 shares of Quince Therapeutics, Inc. - Common Stock, par value $0.001 per share (QNCX). This represents 26% of the company’s total 1,019,878 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
26%
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
1
Latest
Q2 2026
Rows shown
1-1 of 1
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 260,094 | $4,742,596 | +$4,742,596 | $18.19 | 25 |